TIZIANA LIFE SCIENCES LTD |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7403 USD | +8.71% |
|
+18.89% | +32.20% |
Presenter SpeechKunwar Shailubhai (Executives)Hello. My name is Kunwar Shailubhai. I'm CEO and...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company. The Company develops transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Crohn's Disease and KRAS+ NSCLC. Its pipeline candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501) and Milciclib (TZLS-201). Foralumab (TZLS-401) is a fully human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohnâs and neurodegenerative diseases. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +32.20% | 68.31M | |
| +34.41% | 50.85B | |
| +0.53% | 42.82B | |
| +49.62% | 42.03B | |
| -4.96% | 29.55B | |
| +10.97% | 26.11B | |
| -21.66% | 19.13B | |
| +8.33% | 13.05B | |
| +27.13% | 12.16B | |
| +24.41% | 12.08B |
- Stock Market
- Equities
- TLSA Stock
- News Tiziana Life Sciences Ltd
- Transcript : Tiziana Life Sciences PLC - Special Call
